Jeevan Scientific Technology Limited has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) to expand the bed capacity at its Bioavailability/Bioequivalence (BA/BE) Study Centre in Hyderabad. The expansion increases the facility’s capacity from 132 general beds and 06 ICU beds to 156 general beds and 08 ICU beds, enhancing the company’s ability to conduct higher volumes of clinical studies.

The approval follows a successful regulatory inspection conducted by the CDSCO on June 24, 2026. Jeevan Scientific Technology submitted an application for the enhancement, which was processed under the existing regulatory framework. The company disclosed the development on August 01, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Facility Expansion Details

The study centre is located at Plot No. B-17, TIE Phase II, Balanagar, Hyderabad-500037, Telangana. The approved changes reflect a strategic upgrade to the company’s clinical research infrastructure.

The increase allows for a net addition of 24 beds across both categories. This infrastructure upgrade is designed to strengthen operational capabilities and support future business growth through increased study throughput.

Operational Impact

Management indicated that the enhanced capacity will enable the company to undertake a higher volume of Bioavailability/Bioequivalence studies. The expansion addresses potential bottlenecks in scheduling and patient accommodation, allowing for more efficient trial execution.

Jeevan Scientific Technology emphasized its commitment to maintaining high standards of quality, regulatory compliance, and patient safety. The company stated that the upgraded facility will continue to adhere to strict regulatory protocols while expanding its service offerings to clients in the pharmaceutical sector.

What the Numbers Show

The expansion represents a 17.4% increase in total bed capacity (from 138 to 164 beds). While the general bed capacity grows by 18.2%, the ICU bed capacity sees a larger proportional jump of 33.3% (from 06 to 08 beds). This disproportionate increase in ICU beds suggests a strategic focus on handling more complex or high-risk clinical trials that require intensive monitoring, potentially allowing the company to bid for more specialized and higher-value contracts in the CRO space.

Jeevan Scientific Technology Limited reported a standalone net profit of ₹165.01 lakh for the financial year ended March 31, 2026, a significant increase from ₹73.57 lakh in the previous year. Revenue from operations for the year rose to ₹5,393.13 lakh from ₹4,360.99 lakh in FY25. The statutory auditors, M/s. Pavuluri & Co., issued an audit report with an unmodified opinion on the financial results.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a standalone net profit of ₹159.48 lakh, a turnaround from a loss of ₹133.71 lakh in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹1,837.73 lakh, compared to ₹892.48 lakh in Q4FY25. On a consolidated basis, net profit for the year was ₹103.33 lakh, compared to ₹5.90 lakh in the prior year, while revenue increased to ₹6,153.71 lakh from ₹4,684.36 lakh.

Standalone Financial Results (₹ in Lakhs)

Board Decisions

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. Additionally, the Board appointed M/s. KP & Associates, Chartered Accountants, as Internal Auditors for FY 2026-27. The company also granted 4,80,000 stock options to eligible employees pursuant to the JSTL ESOP Scheme 2016.

ESOP Allotment

Pursuant to the exercise of options under the JSTL ESOP Scheme 2016, the company allotted 1,61,250 equity shares of ₹10 each to eligible employees. The total issued share capital post-allotment stands at 2,00,80,215 equity shares. The shares were allotted on May 29, 2026, and rank pari passu with existing shares.